|
||
Brief Definitive Report |
cwang{at}midway.uchicago.edu
| Abstract |
|---|
|
|
|---|
Key Words: infection MHC vaccine N-formylated peptides Mycobacterium tuberculosis
H2-M3 is an MHC class Ib molecule that has a unique specificity for N-formylated hydrophobic peptides derived from mitochondria and bacteria 1718. Given that class Ia molecules do not bind N-formylated peptides appreciably 19, M3 may have been selected in evolution for the specialized presentation of this conserved structure of bacterial peptides. Three listerial antigens presented by M3 have been defined: LemA, Fr 38, and AttM 202122. Each antigen is recognized by CTLs from infected animals. Adoptive transfer of M3-restricted, LemA-specific CTLs can provide protective immunity against listerial infection, indicating that M3-restricted T cells may play a role in host defense against intracellular bacterial infection 23.
Recently, we have shown that M3 surface expression is undetectable in most cell types due to the lack of endogenous antigens. The majority of M3 is retained in an immature peptide-receptive form and traffics rapidly to the cell surface upon the addition of exogenous N-formylated peptide 24. This property allows us to search for novel pathogen-derived peptides that bind to M3 in normal APCs. Identification of bacterial peptides that are able to prime an M3-restricted CTL response will raise the prospect of using these peptides in vaccine development.
In this study, we identified M3-binding peptides derived from Mtb. We showed that CTLs with specificity for N-formylated Mtb peptides can be generated in mice. These T cells are capable of lysing Mtb-infected macrophages. In addition, M3-restricted N-formylated peptide–specific T cells are present in Mtb-infected mice, suggesting that the M3-restricted T cells may contribute to the defense against mycobacterial infection. These N-formylated M3-binding peptides identified from Mtb, a prominent human pathogen, may prove useful in the search for functional homologues of M3 in humans.
![]()
Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Tuberculosis is a leading cause of infectious mortality in the world 1. The causative agent of tuberculosis, Mycobacter-ium tuberculosis (Mtb), is an intracellular bacterial pathogen that resides within phagosomes of infected macrophages. Despite the noncytosolic location of Mtb, endogenous Mtb-derived antigens can be presented to CD8+ T cells, presumably through an alternative MHC class I antigen processing pathway 234. Studies of experimental tuberculosis in mice indicate that CD8+ T cells contribute to immune defense against Mtb by releasing cytokines such as IFN-
and TNF-
and directly lysing infected cells 5678910. Although the identification of Mtb antigens for T cell recognition is critical in the design of T cell–based vaccines, relatively few T cell epitopes for Mtb-specific CD8+ T cells have been identified. Among them are MHC class Ia–binding peptides derived from 38-kD lipoprotein 11, 19-kD lipoprotein 12, and early secretory antigenic target 6 13 and CD1-bound lipid antigens derived from the mycobacterial cell wall 1415. A recent study has shown that some human Mtb-reactive CTLs are not restricted by MHC class Ia nor by CD1 molecules, suggesting that other class Ib molecules may be involved in presenting Mtb antigens 16.
![]()
Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Abs and Peptides.
Abs used in this study include: FITC-conjugated mAbs specific for hamster IgG; CD4 (RM4-5); TCR-β (H57-597); Vβ5 (MR9-4); Vβ6 (RR4-7); Vβ7 (TR310); Vβ8 (MR5-2); Vβ9 (MR10-2); Vβ12 (MR11-1); Vβ14 (14-2); and V3
(RR3-16); and PE-conjugated mAbs specific for CD8
(53-6.7); Vβ2 (B20.6); Vβ3 (KJ25); Vβ4 (KT4); Vβ10 (B21.5); Vβ11 (RR3-15); Vβ13 (RR12-3); V
2 (B20.1); V
8 (B21.14); and V
11 (RR8-1) (BD PharMingen). The hamster mAb130 was purified as described previously 24. Synthetic peptides were purchased from Research Genetics. Peptide sequences are described in Table . All peptides were >90% pure as determined by mass spectrometry. Peptides were dissolved in DMSO at concentrations of 10 mM.
|
Cell Lines and Cell Cultures.
Fibroblast cell lines were maintained in RPMI 1640 (Mediatech) with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 20 mM Hepes, 50 µM 2-ME, penicillin, and streptomycin (RPMI 10), and the macrophage cell line P388 was cultured in DMEM (Mediatech) containing 10% FBS. For CTL assays, cells were harvested with 0.2% collagenase (type IV) and EDTA-saline (140 mM NaCl, 5 mM KCl, 12.5 mM Na2HPO4, 5.8 mM NaH2PO4, 0.2% glucose, and Na2EDTA, pH 7.2). TR8.4a is a derivative of the B10.CAS2 fibroblast cell line that has been transfected with genomic DNA encoding M3wt 26. P388-M3 is a macrophage cell line that has been transfected with M3 cDNA under the control of CMV promoter.
Computer-aided Search of M3-binding Peptide and Computer Modeling.
The Mtb sequences in The Sanger Center database were searched with the Findpattern program (Genetic Computer Group) allowing no mismatches with the following sequence: fM(Y,F,W,I,L)(Y,F,I,L,V)ZXX (Z, amino acid with nonpolar side chain; X, any amino acid; reference 27). 41 peptides were identified that bear this motif. We modeled 20 such peptides into the binding groove of the M3/MTF crystal structure with program O on a Silicon Graphics machine 2829. The backbone conformation of the peptide was left unchanged, and rotameric states of the new side chains were assigned to optimize van der Waals interactions and avoid steric hindrance.
Induction of M3 on the Cell Surface by Mtb Peptides.
Splenocyte suspensions were prepared from C57BL/6 (B6) mouse spleens by mechanical disruption in RPMI 10. RBCs were removed by hypotonic lysis. One million cells were incubated in RPMI 10 with or without peptides overnight at 37°C. Cells were harvested and washed three times with PBS before cell surface staining experiments. M3 staining was detected by adding 100 µl of hybridoma supernatants (mAb130) followed by mouse anti–hamster IgG FITC. Staining with each reagent was performed for 30 min on ice in HBSS (Life Technologies) containing 2% FBS and 0.1% sodium azide (Sigma Aldrich), followed by washing with the same buffer. The stained cells were analyzed by flow cytometry using a FACSCaliberTM (Becton Dickinson) with CELLQuestTM software.
Generation and Maintenance of Mtb-specific CTL Lines.
5 x 106 splenocytes from B6 mice were cultured in 5 ml of RPMI 10 in the presence of 10 µM Mtb peptide at 37°C. After overnight incubation, cells were harvested, washed three times with PBS, and inactivated by gamma irradiation (1,500 rads). B6 mice were primed with peptide-coated splenocytes through intraperitoneal injection and footpad injection. After 1 wk, the mice were killed, and their spleen cells were incubated with 10 µM peptides in RPMI 10 at the concentration of 107 cells per milliliter. Cultures were restimulated weekly with peptide-pulsed syngenic splenocytes (2–5 x 106 cells per milliliter) and maintained in supplemented Mishell Dutton medium with IL-2 supplement (20 U/ml). IL-2 for restimulations was partially purified from the supernatant of EL4.IL2 cells (American Type Culture Collection), assayed, and used as described in reference 30.
Culture and Infection of Macrophages.
Macrophages were grown from bone marrow precursors of B6 mice. In brief, cells were eluted from the femur and tibia bones of mice in DMEM 10. Cells were washed twice in DMEM, and 1–3 x 106 cells were plated in LabTek PS petri dishes (Fisher Scientific) in 25 ml DMEM 10, 1 mM sodium pyruvate (Sigma Aldrich), 2 mM L-glutamine (Life Technologies, Inc.), and 33% supernatant from L cell fibroblasts cultured for 5–7 d. All reagents were LPS-free, and no antibiotics were used. Medium was changed once after 2–3 d of culture. On day 5, medium was replaced with DMEM 10, 1 mM sodium pyruvate, and 2 mM L-glutamine. Cells were then infected with Mtb at a multiplicity of infection of 2–5. The percentage of infection was estimated in each experiment by staining aliquots of cells by the Kinyoun method for acid-fast bacteria (Difco Laboratories, Inc.). After 15–48 h of infection (depending on the assay), adherent cells were prepared for use as targets in CTL assays.
CTL Assays.
One million target cells were incubated in RPMI 10 with or without 10 µM peptide overnight. After incubation with peptide, cells were washed free of excess peptide and labeled with 100 µCi [51Cr]–sodium chromate for 1 h at 37°C. For infected macrophages, cells were washed twice with ice-cold PBS, incubated for 20 min on ice, and harvested by forceful pipetting before labeling in Teflon jars (Savillex). Target cells (104 cells) were added to round-bottomed microtiter wells containing effector cells. After 4 h, 100 µl of supernatant from each well was collected and assayed for 51Cr release. The percentage of specific lysis = (experimental release – spontaneous release)/(maximal release – spontaneous release) x 100.
IFN-
Assay.
CTLs (105 cells/well) were stimulated with gamma-irradiated B6 splenocytes (105 cells/well) in a final volume of 200 µl of RPMI 10 in the presence or absence of 10 µM Mtb peptide. After 48 h, the culture supernatants were harvested, and the levels of IFN-
were quantitated by sandwich ELISA using commercial mAb pairs (BD PharMingen) according to the manufacturer's instructions.
In Vitro IFN-
Production by Lymphocytes from Mtb-infected Mice.
B6 and KbDb knockout (KO) mice (in B6 background; reference 31) were infected intravenously via tail vein with 105 live bacilli. At 10 and 21 d after infection, lungs, pulmonary lymph nodes, and spleens were harvested. Single-cell suspensions were obtained by crushing the organs in cell strainders (Becton Dickinson). RBCs were removed by hypotonic lysis, and the cells were washed extensively. Cells were resuspended in T cell medium (DMEM supplemented with 10% FBS, 1 mM sodium pyruvate, 2 mM L-glutamine, 25 mM Hepes, and 1% nonessential amino acids) and plated onto culture dishes for 1 h at 37°C to deplete macrophages. Lung and lymph node cells (8 x 104 and 2 x 105 cells per well, respectively) were stimulated with P388–M3 (1:1 ratio), pulsed with either a mixture of Mtb peptides (TB1-7, 2 µM each) or LemA in the presence or absence of an anti-M3 Ab (mAb130). Each condition was plated in triplicate wells in 96-well plates; each well contained a total volume of 200 µl. Spleen cells (2 x 105 cells/well) were stimulated as above, except P388–M3 pulsed with 10 µM of each TB peptide were also included as stimulators. After a 4-d incubation at 37°C, supernatants from each well were filtered with 0.45-µm filter to remove Mtb before testing for IFN-
.
| Results |
|---|
|
|
|---|
|
|
Mtb Peptide–specific CTLs Can Effectively Kill Mtb-infected Macrophages.
To assess whether Mtb peptide–induced CTLs can recognize naturally processed mycobacterial antigens, we performed CTL assays using Mtb-infected macrophages as target cells. M3 surface expression was not detectable on uninfected macrophages. Upon infection, expression increased to low but detectable levels (data not shown). The infected macrophages were specifically lysed by all the Mtb peptide-specific CTL lines (Fig. 3) but were insensitive to the lysis by a Listeria-specific M3-restricted CTL clone, D7 33. The lysis of infected macrophages by M3-restricted Mtb peptide–specific CTLs indicates that these N-formylated peptides are naturally processed and presented by M3 in Mtb-infected macrophages. Macrophages infected for 12–18 h were already recognized by M3-restricted CTL, although in some experiments lysis was improved if the infection of macrophages was allowed to progress for 48 h before use in the CTL assay.
|
β TCRs, and most of the lines use different combinations of the V
and the Vβ segments, suggesting that the T cell repertoire for M3-restricted responses is not limited. Four of the Mtb-specific CTL lines express the CD8 coreceptor, while the other four CTLs do not express CD4 or CD8 coreceptors. As both CD8+ and dominant negative (DN) CTLs can lyse Fas-negative target cells such as peptide-pulsed fibroblasts, it is likely that both types of M3-restricted CTLs can lyse the targets via the granule exocytosis pathway. However, in the case of the CD1-restricted, Mtb-specific CTLs, the CD8+ CD1-restricted CTLs lysed infected cells by a granule-dependent mechanism, whereas the DN CD1-restricted CTLs lysed targets through Fas–FasL interaction 34.
|
by T cells is one of the protective mechanisms against bacterial pathogens and is particularly crucial in controlling tuberculosis 3536. To test the ability of Mtb-specific CTLs to secrete IFN-
, we measured IFN-
secreted in response to peptide-pulsed B6 splenocytes. As shown in Table , all of the CTLs produced significant amounts of IFN-
in response to stimulation with Mtb peptide–pulsed splenocytes. Thus, these M3-restricted, Mtb-specific CTLs could directly lyse the infected cells and release IFN-
to modulate the cell-mediated immune response against Mtb.
M3-restricted T Cells Participate in Immune Response to Mtb In Vivo.
Although the M3-restricted CTL lines were capable of recognizing antigen presented by infected macrophages, it remained to be determined whether T cells specific for these N-formylated peptides were elicited in response to Mtb infection in mice. Lymphocytes were isolated from Mtb-infected mice at 10 and 21 d after infection and examined for IFN-
production by restimulating in vitro with either a mixture of TB peptides (TB1-7) or individual TB peptide. Both KbDb KO and B6 mice were examined to determine whether M3-restricted responses are augmented in the absence of class Ia molecules. At 21 d after infection, lymphocytes harvested from lungs, lymph nodes, and spleens of infected KbDb KO and B6 mice secreted IFN-
upon in vitro stimulation with TB1-7, but not with LemA peptide (Fig. 3 B). The response was blocked by the addition of anti-M3 Ab (mAb130), suggesting that TB peptide–specific, M3-restricted T cells are present in Mtb-infected mice. Similar results were obtained with lymphocytes isolated from infected mice at 10 d after infection, but the magnitude of the response was lower (data not shown). Three out of the seven TB peptides, TB2, TB4, and TB7, readily induced IFN-
from the spleen cells of infected B6 and KbDb KO mice (Fig. 3 C), but not from uninfected mice (data not shown). The response to TB1 was only detected from infected KbDbKO mice. In addition, lymphocytes from infected KbDb KO mice secreted substantially larger amounts of IFN-
in response to TB peptides, indicating that M3-restricted T cells are enriched in KbDb KO mice. Taken together, these results suggest that N-formylated M3-binding peptides are effectively presented during Mtb infection, and the resulting M3-restricted T cells may contribute to the immunity against Mtb.
| Discussion |
|---|
|
|
|---|
The unique ligand specificity of M3 may contribute to its efficacy in antigen presentation by allowing N-formylated antigenic peptides access to a pool of empty M3 in the endoplasmic reticulum without competition from many self-peptides 24. During infection, presentation of N-formylated bacterial peptides by M3 is rapid and undiluted, which might provide a potent activation signal to M3-restricted T cells. Consistent with this notion, Kerksiek et al. 37 have shown that M3-restricted responses appear to be earlier and more prominent than class Ia–restricted responses in the primary infection of mice with Listeria monocytogenes. In our studies, the response to the N-formylated TB peptides was stronger at 21 d after infection compared with 10 d after infection, suggesting that the kinetics of the response may vary with different pathogens. N-formyl modification is a feature common to bacterial proteins. Thus, it is possible that M3 might be able to present antigens derived from a variety of intracellular bacteria, and M3-restricted responses might contribute to the defense against infection by a wide range of intracellular pathogens.
Limited polymorphism of M3 suggests that M3 may have evolved to present conserved and unique ligands to T cells. Focusing the immune response on common microbial entities that are rare or absent from host cells can broaden the host specificity against infectious agents without increasing the risk of autoimmunity. The CD1 molecules exemplify this strategy by presenting bacterial lipids to T cells 1415. N-formylated peptides are extremely rare in mammalian cells but serve as a widely used signal sequence for protein secretion in bacteria. Therefore, it would be advantageous for the host to preserve such antigen presentation through evolution. Although Southern blot analysis failed to detect M3 orthologs in humans 26, it remains to be determined whether functional homologues of M3 exist in humans. HLA-E and Qa-1 do not share striking sequence similarity to each other, although each appear to have evolved to bind leader peptides of class Ia molecules in humans and mice, respectively 3839.
MHC-unrestricted, Mtb-specific CTLs have been identified in humans 16. However, the antigen(s) and the restriction element(s) for these CTLs have not been determined. Our results suggest that if a human homologue of M3 exists, it would be possible to elicit CTL responses from infected individuals by in vitro stimulation with Mtb-derived N-formylated peptides. Currently, we are attempting to use the M3-binding peptides described in our study as candidate peptides for developing human CTLs. If this approach succeeds, N-formylated peptides presented by a nonpolymorphic MHC molecule could potentially be used as novel vaccines against Mtb infection in a broad range of recipients.
| Acknowledgments |
|---|
T. Chun is a recipient of postdoctoral fellowship from the Cancer Research Institute. N.M. Chiu is a trainee of the Medical Scientist Training program. N.V. Serbina is a trainee on the National Institutes of Health (NIH)/National Cancer Institute training grant T32 CA82084. This work was supported by NIH grants AI-40310 (to C.-R. Wang) and AI-37859 (to J.L. Flynn) and a Searle scholar's award to C.-R. Wang.
Submitted: 29 March 2000
Revised: 9 April 2001
Accepted: 10 April 2001
| References |
|---|
|
|
|---|
Enarson D.A. & Murray J.F.. Global epidemiology of tuberculosis, Rom W.M. & Gary S.M., Tuberculosis, 1996, 57–75, Little, Brown and Company, New York.
Mazzaccaro R.J., Gedde M., Jensen E.R., van Santen H.M., Ploegh H.L., Rock K.L. & Bloom B.R.. Major histocompatibility class I presentation of soluble antigen facilitated by Mycobacterium tuberculosis infection, Proc. Natl. Acad. Sci. USA., 93, 1996, 11786–11791.
Teitelbaum R., Cammer M., Maitland M.L., Freitag N.E., Condeelis J. & Bloom B.R.. Mycobacterial infection of macrophages results in membrane-permeable phagosomes, Proc. Natl. Acad. Sci. USA., 96, 1999, 15190–15195.
Canaday D.H., Ziebold C., Noss E.H., Chervenak K.A., Harding C.V. & Boom W.H.. Activation of human CD8+
β TCR+ cells by Mycobacterium tuberculosis via an alternate class I MHC antigen-processing pathway, J. Immunol., 162, 1999, 372–379.
Orme I.M. & Collins F.M.. Adoptive protection of the Mycobacterium tuberculosis-infected lung. Dissociation between cells that passively transfer protective immunity and those that transfer delayed-type hypersensitivity to tuberculin, Cell. Immunol., 84, 1984, 113–120.[Medline]
Flynn J.L., Goldstein M.M., Triebold K.J., Koller B. & Bloom B.R.. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection, Proc. Natl. Acad. Sci. USA., 89, 1992, 12013–12017.
Serbina N.V. & Flynn J.L.. Early emergence of CD8+ T cells primed for production of type 1 cytokines in the lungs of Mycobacterium tuberculosis-infected mice, Infect. Immun., 67, 1999, 3980–3988.
Feng C.G., Bean A.G., Hooi H., Briscoe H. & Britton W.J.. Increase in
interferon-secreting CD8+, as well as CD4+, T cells in lungs following aerosol infection with Mycobacterium tuberculosis, Infect. Immun., 67, 1999, 3242–3247.
Zhu X., Stauss H.J., Ivanyi J. & Vordermeier H.M.. Specificity of CD8+ T cells from subunit-vaccinated and infected H-2b mice recognizing the 38 kDa antigen of Mycobacterium tuberculosis, Int. Immunol., 9, 1997, 1669–1676.
De Libero G., Flesch I. & Kaufmann S.H.. Mycobacteria-reactive Lyt-2+ T cell lines, Eur. J. Immunol., 18, 1988, 59–66.[Medline]
Vordermeier H.M., Zhu X. & Harris D.P.. Induction of CD8+ CTL recognizing mycobacterial peptides, Scand. J. Immunol., 45, 1997, 521–526.[Medline]
Mohagheghpour N., Gammon D., Kawamura L.M., van Vollenhoven A., Benike C.J. & Engleman E.G.. CTL response to Mycobacterium tuberculosisidentification of an immunogenic epitope in the 19-kDa lipoprotein, J. Immunol., 161, 1998, 2400–2406.
Lalvani A., Brookes R., Wilkinson R.J., Malin A.S., Pathan A.A., Andersen P., Dockrell H., Pasvol G. & Hill A.V.. Human cytolytic and interferon
-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis, Proc. Natl. Acad. Sci. USA, 95, 1998, 270–275.
Beckman E.M., Porcelli S.A., Morita C.T., Behar S.M., Furlong S.T. & Brenner M.B.. Recognition of a lipid antigen by CD1-restricted
β+ T cells, Nature, 372, 1994, 691–694.[Medline]
Sieling P.A., Chatterjee D., Porcelli S.A., Prigozy T.I., Mazzaccaro R.J., Soriano T., Bloom B.R., Brenner M.B., Kronenberg M. & Brennan P.J.. CD1-restricted T cell recognition of microbial lipoglycan antigens, Science., 269, 1995, 227–230.
Lewinsohn D.M., Alderson M.R., Briden A.L., Riddell S.R., Reed S.G. & Grabstein K.H.. Characterization of human CD8+ T cells reactive with Mycobacterium tuberculosis-infected antigen-presenting cells, J. Exp. Med., 187, 1998, 1633–1640.
Shawar S.M., Vyas J.M., Rodgers J.R., Cook R.G. & Rich R.R.. Specialized functions of major histocompatibility complex class I molecules. II. Hmt binds N-formylated peptides of mitochondrial and prokaryotic origin, J. Exp. Med., 174, 1991, 941–944.
Lindahl K.F., Byers D.E., Dabhi V.M., Hovik R., Jones E.P., Smith G.P., Wang C.-R., Xiao H. & Yoshino M.. H2-M3, a full-service class Ib histocompatibility antigen, Annu. Rev. Immunol., 15, 1997, 851–879.[Medline]
Shawar S.M., Vyas J.M., Shen E., Rodgers J.R. & Rich R.R.. Differential amino-terminal anchors for peptide binding to H-2M3a or H-2Kb and H-2Db, J. Immunol., 151, 1993, 201–210.[Abstract]
Gulden P.H., Fischer P., Sherman N.E., Wang W., Engelhard V.H., Shabanowitz J., Hunt D.F. & Pamer E.G.. A Listeria monocytogenes pentapeptide is presented to cytolytic T lymphocytes by the H2-M3 MHC class Ib molecule, Immunity., 5, 1996, 73–79.[Medline]
Lenz L.L., Dere B. & Bevan M.J.. Identification of an H2-M3-restricted Listeria epitopeimplications for antigen presentation by M3, Immunity., 5, 1996, 63–72.[Medline]
Princiotta M.F., Lenz L.L., Bevan M.J. & Staerz U.D.. H2-M3 restricted presentation of a Listeria-derived leader peptide, J. Exp. Med., 187, 1998, 1711–1719.
Nataraj C., Brown M.L., Poston R.M., Shawar S.M., Rich R.R., Lindahl K.F. & Kurlander R.J.. H2-M3wt-restricted, Listeria monocytogenes-specific CD8 T cells recognize a novel, hydrophobic, protease-resistant, periodate-sensitive antigen, Int. Immunol., 8, 1996, 367–378.
Chiu N.M., Chun T., Fay M., Mandal M. & Wang C.-R.. The majority of H2-M3 is retained intracellularly in a peptide-receptive state and traffics to the cell surface in the presence of N- formylated peptides, J. Exp. Med., 190, 1999, 423–434.
Havlir D.V., Wallis R.S., Boom W.H., Daniel T.M., Chervenak K. & Ellner J.J.. Human immune response to Mycobacterium tuberculosis antigen, Infect. Immun., 59, 1991, 665–670.
Wang C.-R., Loveland B.E. & Lindahl K.F.. H-2M3 encodes the MHC class I molecule presenting the maternally transmitted antigen of the mouse, Cell., 66, 1991, 335–345.[Medline]
Cole S.T., Brosch R., Parkhill J., Garnier T., Churcher C., Harris D., Gordon S.V., Eiglmeier K., Gas S. & Barry C.E. III. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence, Nature, 393, 1998, 537–544.[Medline]
Wang C.-R., Castaño A.R., Peterson P.A., Slaughter C., Lindahl K.F. & Deisenhofer J.. Nonclassical binding of formylated peptide in crystal structure of the MHC class Ib molecule H2- M3, Cell., 82, 1995, 655–664.[Medline]
Jones T.A., Zou J.Y., Cowan S.W. & Kjeldgaard M.. Improved methods for binding protein models in electron density maps and the location of errors in these models, Acta Crystallogr. A, 47, 1991, 110–119.[Medline]
Dabhi V.M. & Lindahl K.F.. MtDNA-encoded histocompatibility antigens, Methods Enzymol., 260, 1995, 466–485.[Medline]
Vugmeyster Y., Glas R., Perarnau B., Lemonnier F.A., Eisen H. & Ploegh H.. Major histocompatibility complex (MHC) class I KbDb–/– deficient mice possess functional CD8+ T cells and natural killer cells, Proc. Natl. Acad. Sci. USA, 95, 1998, 12492–12497.
Nataraj C., Huffman G.R. & Kurlander R.J.. H2M3wt-restricted, Listeria monocytogenes-immune CD8 T cells respond to multiple formylated peptides and to a variety of gram-positive and gram-negative bacteria, Int. Immunol., 10, 1998, 7–15.
Nancy M.C., Wang B., Kerksiek K.M., Kurlander R.J., Pamer E.G. & Wang C.-R.. The selection of M3-restricted T cells is dependent on M3 expression and presentation of N-formylated peptides in the thymus, J. Exp. Med., 190, 1999, 1869–1878.
Stenger S., Mazzaccaro R.J., Uyemura K., Cho S., Barnes P.F., Rosat J.P., Sette A., Brenner M.B., Porcelli S.A. & Bloom B.R.. Differential effects of cytolytic T cell subsets on intracellular infection, Science, 276, 1997, 1684–1687.
Flynn J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A. & Bloom B.R.. An essential role for interferon
in resistance to Mycobacterium tuberculosis infection, J. Exp. Med., 178, 1993, 2249–2254.
Cooper A.M., Dalton D.K., Stewart T.A., Griffin J.P., Russell D.G. & Orme I.M.. Disseminated tuberculosis in interferon
gene–disrupted mice, J. Exp. Med., 178, 1993, 2243–2247.
Kerksiek K.M., Busch D.H., Pilip I.M., Allen S.E. & Pamer E.G.. H2-M3–restricted T cells in bacterial infectionrapid primary but diminished memory responses, J. Exp. Med., 190, 1999, 195–204.
Braud V., Jones E.Y. & McMichael A.. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9, Eur. J. Immunol., 27, 1997, 1164–1169.[Medline]
Kurepa Z., Hasemann C.A. & Forman J.. Qa-1b binds conserved class I leader peptides derived from several mammalian species, J. Exp. Med., 188, 1998, 973–978.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|